{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:15:57Z","timestamp":1744719357448,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10689-020-00222-0","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T02:22:57Z","timestamp":1609986177000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic evaluation of patients and families with concern for hereditary endocrine tumor syndromes"],"prefix":"10.1007","volume":"21","author":[{"given":"Jennifer L.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pilarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-5363","authenticated-orcid":false,"given":"Pamela","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"5","key":"222_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/qjmed\/hcq020","volume":"103","author":"HD White","year":"2010","unstructured":"White HD, Blair J, Pinkney J, Cuthbertson DJ, Day R, Weber A, Macfarlane IA (2010) Improvement in the care of multiple endocrine neoplasia type 1 through a regional multidisciplinary clinic. QJM 103(5):337\u2013345. https:\/\/doi.org\/10.1093\/qjmed\/hcq020","journal-title":"QJM"},{"issue":"4","key":"222_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2265.2008.03324.x","volume":"70","author":"CR Pieterman","year":"2009","unstructured":"Pieterman CR, Schreinemakers JM, Koppeschaar HP, Vriens MR, Rinkes IH, Zonnenberg BA et al (2009) Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. ClinEndocrinol 70(4):575\u2013581. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03324.x","journal-title":"ClinEndocrinol"},{"issue":"8","key":"222_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"L Susswein","year":"2015","unstructured":"Susswein L, Marshall M, Nusbaum R, Postula K, Weissman M, Yackowski L et al (2015) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18(8):823\u2013832. https:\/\/doi.org\/10.1038\/gim.2015.166","journal-title":"Genet Med"},{"key":"222_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-018-0106-2","author":"E Walker","year":"2018","unstructured":"Walker E, Carnevale J, Pedley C, Blanco A, Chan S, Collisson E et al (2018) Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. https:\/\/doi.org\/10.1007\/s10689-018-0106-2","journal-title":"Fam Cancer"},{"issue":"4","key":"222_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/COC.0000000000000073","volume":"39","author":"A Stuckey","year":"2016","unstructured":"Stuckey A, Febbaro T, Laprise J, Wilbur J, Lopes V, Robison K (2016) Adherence patterns to national comprehensive cancer network guidelines for referral of women with breast cancer to genetics professionals. Am J ClinOncol 39(4):363\u2013367. https:\/\/doi.org\/10.1097\/COC.0000000000000073","journal-title":"Am J ClinOncol"},{"issue":"17","key":"222_CR6","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1002\/cncr.31628","volume":"124","author":"R Brand","year":"2018","unstructured":"Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters M et al (2018) Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 124(17):3520\u20133527. https:\/\/doi.org\/10.1002\/cncr.31628","journal-title":"Cancer"},{"issue":"6","key":"222_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"P Beitsch","year":"2019","unstructured":"Beitsch P, Whitworth P, Hughes K, Patel R, Rosen B, Compagnoni G et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J ClinOncol 37(6):453\u2013460. https:\/\/doi.org\/10.1200\/JCO.18.01631","journal-title":"J ClinOncol"},{"issue":"8","key":"222_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/ERC-17-0196","volume":"24","author":"JP Dumanski","year":"2017","unstructured":"Dumanski JP, Rasi C, Bj\u00f6rklund P, Davies H, Ali AS, Gr\u00f6nberg M et al (2017) A MUTYHgermline mutation is associated with small intestinal neuroendocrine tumors. EndocrRelat Cancer 24(8):427\u2013443. https:\/\/doi.org\/10.1530\/ERC-17-0196","journal-title":"EndocrRelat Cancer"},{"issue":"4","key":"222_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s40142-015-0075-9","volume":"3","author":"MI Roche","year":"2015","unstructured":"Roche MI, Berg JS (2015) Incidental findings with genomic testing: implications for genetic counseling practice. Curr Genet Med Rep 3(4):166\u2013176. https:\/\/doi.org\/10.1007\/s40142-015-0075-9","journal-title":"Curr Genet Med Rep"},{"issue":"1","key":"222_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10689-010-9399-5","volume":"10","author":"AK Win","year":"2011","unstructured":"Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10(1):1\u20139. https:\/\/doi.org\/10.1007\/s10689-010-9399-5","journal-title":"Fam Cancer"},{"issue":"2","key":"222_CR11","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.3747\/co.25.3707","volume":"25","author":"KJ Jerzak","year":"2018","unstructured":"Jerzak KJ, Mancuso T, Eisen A (2018) Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. CurrOncol (Toronto, Ont.) 25(2):e176\u2013e180. https:\/\/doi.org\/10.3747\/co.25.3707","journal-title":"CurrOncol (Toronto, Ont.)"},{"key":"222_CR12","doi-asserted-by":"publisher","first-page":"747318","DOI":"10.1155\/2013\/747318","volume":"2013","author":"P Apostolou","year":"2013","unstructured":"Apostolou P, Fostira F (2013) Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013:747318. https:\/\/doi.org\/10.1155\/2013\/747318","journal-title":"Biomed Res Int"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-020-00222-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00222-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:29:29Z","timestamp":1643369369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-020-00222-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1007\/s10689-020-00222-0","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"type":"print","value":"1389-9600"},{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"27 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Lawrence Kirschner has a patent on the identification of the <i>PRKAR1A<\/i> gene (Carney complex; United States Patent 6,759,525 Stratakis, et al. July 6, 2004). There are no additional conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by The Ohio State University (OSU) Institutional Review Board. This study was performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}